NewAmsterdam Pharma (NAMS) Expected to Announce Quarterly Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.4726) per share and revenue of $1.8770 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. The business had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. On average, analysts expect NewAmsterdam Pharma to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $27.79 on Monday. The stock has a market cap of $3.25 billion, a P/E ratio of -15.53 and a beta of 0.10. NewAmsterdam Pharma has a 1 year low of $21.14 and a 1 year high of $42.21. The firm’s 50 day moving average price is $32.16 and its 200-day moving average price is $32.65.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 105,000 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $738,870.02. This represents a 81.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 210,000 shares of company stock valued at $6,713,550. Insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors have recently modified their holdings of NAMS. Wells Fargo & Company MN increased its position in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. Empowered Funds LLC purchased a new position in NewAmsterdam Pharma during the fourth quarter worth $85,000. Persistent Asset Partners Ltd purchased a new position in NewAmsterdam Pharma during the fourth quarter worth $138,000. The Manufacturers Life Insurance Company increased its position in NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares during the last quarter. Finally, Guggenheim Capital LLC bought a new position in NewAmsterdam Pharma during the fourth quarter valued at $224,000. 89.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Finally, Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.42.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.